Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase IIa, Double-blind, Randomized, Placebo-controlled Study of the Efficacy and Safety of SOM3355 in Huntington's Disease (HD) Patients With Chorea Movements.

NCT03575676 is registered in ClinicalTrials.gov with SOM Innovation Biotech SA as lead sponsor.

NCT NCT03575676
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03575676 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase IIa, Double-blind, Randomized, Placebo-controlled Study of the Efficacy and Safety of SOM3355 in Huntington's Disease (HD) Patients With Chorea Movements.
Lead sponsor
SOM Innovation Biotech SA
Phase
Phase 2
Overall status
Completed
Start date
August 8, 2018
Completion date
August 22, 2019
Enrollment
32 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

huntington's chorea